{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"11.8","value":"6.5"},{"groupId":"OG001","lowerLimit":"7.3","upperLimit":"7.3","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.","dispersionType":"Full Range","groups":[{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (560mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG000","title":"Phase 1: Dose Finding (560 mg)"},{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (840mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG001","title":"Phase 1: Dose Finding (840 mg)"}],"paramType":"MEDIAN","populationDescription":"Median was not reached for Phase 1: Dose Finding (560 mg). Median value provided here was the median and range (min and max).","reportingStatus":"POSTED","timeFrame":"14 Months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}